for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ipsen SA

IPN.PA

Latest Trade

71.90EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

34.20

 - 

104.00

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
71.90
Open
--
Volume
--
3M AVG Volume
2.40
Today's High
--
Today's Low
--
52 Week High
104.00
52 Week Low
34.20
Shares Out (MIL)
83.10
Market Cap (MIL)
6,453.72
Forward P/E
11.55
Dividend (Yield %)
1.30

Next Event

Full Year 2020 Ipsen SA Earnings Release

Latest Developments

More

Ipsen Eyes To Generate EUR 3 Bln By 2024 For Pipeline Expansion

Ipsen Receives FDA Fast Track Designation For Onivyde

Ipsen SA - Ipsen Appoints Philippe Lopes Fernandes As Executive Vice President, Chief Business Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ipsen SA

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Industry

Biotechnology & Drugs

Contact Info

65 Quai Georges Gorse

92100

France

+33.1.58335000

https://www.ipsen.com/

Executive Leadership

Marc de Garidel

Chairman of the Board

David Loew

Chief Executive Officer, Director

Antoine Flochel

Vice Chairman of the Board

Aymeric le Chatelier

Chief Financial Officer, Executive Vice President

Regis Mulot

Chief Human Resource Officer, Executive Vice President

Key Stats

2.18 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

1.9K

2018

2.2K

2019

2.6K

2020(E)

2.7K
EPS (EUR)

2017

4.360

2018

5.910

2019

6.740

2020(E)

7.002
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.38
Price To Book (MRQ)
3.45
Price To Cash Flow (TTM)
42.91
Total Debt To Equity (MRQ)
52.98
LT Debt To Equity (MRQ)
36.40
Return on Investment (TTM)
-1.68
Return on Equity (TTM)
-1.12

Latest News

Latest News

Ipsen expects to generate over $3 billion by 2024 for drug pipeline expansion

French healthcare company Ipsen said on Tuesday that it expects to generate about 3 billion euros ($3.59 billion) by 2024, excluding asset sales, to power the expansion of its drug pipeline.

BRIEF-Ipsen Announces Updated Indication For Dysport For The Treatment Of Spasticity In Children

* IPSEN ANNOUNCES UPDATED INDICATION FOR DYSPORT® (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF SPASTICITY IN CHILDREN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Ipsen Joins Clinical Collaboration To Evaluate Lung And Prostate Cancer Treatments

* IPSEN JOINS CLINICAL COLLABORATION TO EVALUATE CABOZANTINIB (CABOMETYX®) PLUS ATEZOLIZUMAB IN METASTATIC NON-SMALL CELL LUNG CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

BRIEF-Ipsen Obtains FDA's Fast Track designation For ONIVYDE

* OBTAINS FAST TRACK DESIGNATION FROM FDA FOR LIPOSOMAL IRINOTECAN (ONIVYDE®) AS COMBINATION TREATMENT FOR METASTATIC PANCREATIC CANCER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Photocure Enters Into Agreement With Ipsen

* PHOTOCURE ENTERS INTO FINAL AGREEMENT TO REGAIN WORLDWIDE RIGHTS OF HEXVIX

BRIEF-Ipsen Shares Eight Abstracts On Rare Diseases

* IPSEN DEMONSTRATES CONTINUED COMMITMENT TO RARE DISEASES WITH EIGHT ABSTRACTS ACCEPTED AT ENDO 2020 PUBLISHED IN JOURNAL OF ENDOCRINE SOCIETY

BRIEF-Ipsen starts share buyback programme to cover share allocation plan

* IPSEN INITIATES A SHARE BUYBACK PROGRAM TO COVER ITS SHARE ALLOCATION PLAN

Sanofi's head of vaccines leaves for smaller competitor Ipsen

Sanofi's head of vaccines David Loew will quit to become chief executive of Ipsen from July 1, the two French drugmakers said on Friday.

BRIEF-Ipsen Appoints David Loew As Chief Executive Officer

* AYMERIC LE CHATELIER WILL REMAIN IN THE ROLE OF ACTING CEO UNTIL JULY 1ST, 2020 AND WILL CONTINUE IN HIS ROLE OF CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Ipsen Announces Publication Of First Matching-Adjusted Indirect Comparison Of Cabometyx (Cabozantinib) Versus Regorafenib

* IPSEN ANNOUNCES PUBLICATION OF FIRST MATCHING-ADJUSTED INDIRECT COMPARISON OF CABOMETYX® (CABOZANTINIB) VERSUS REGORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA IN ADVANCES IN THERAPY

BRIEF-Ipsen Enters Into Option Agreement With IRICoR, University of Montreal

* ENTERS INTO AN OPTION AGREEMENT WITH IRICOR AND UNIVERSITE DE MONTRÉAL FOR A DISCOVERY-STAGE ONCOLOGY PROGRAM

BRIEF-Photocure In Agreement With Ipsen To Regain Rights For Sales And Marketing Of Hexvix® In Europe

* HAS REACHED AN AGREEMENT WITH IPSEN TO REGAIN RIGHTS FOR SALES AND MARKETING OF HEXVIX(®) IN EUROPE

BRIEF-Ipsen Reports Solid Sales Growth In Q1, Limited COVID-19 Impact

* IPSEN REPORTS SOLID SALES GROWTH IN FIRST QUARTER 2020 WITH LIMITED COVID-19 IMPACT

BRIEF-Ipsen Announces Positive Results From Phase III CheckMate -9ER Trial

* POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE III CHECKMATE -9ER TRIAL EVALUATING CABOMETYX® (CABOZANTINIB) IN COMBINATION WITH OPDIVO® (NIVOLUMAB) IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-Ipsen Provides Update On Palovarotene Clinical Programs

* IPSEN TO REINITIATE PALOVAROTENE DOSING IN PATIENTS 14 YEARS OF AGE AND OLDER WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

BRIEF-Ipsen Suspends Its 2020 Financial Guidance Because Of Coronavirus Crisis

* ON CORONAVIRUS: IPSEN SEES A LIMITED FINANCIAL IMPACT TODAY GIVEN ITS RESILIENT PRODUCT PORTFOLIO COMPRISED MOSTLY OF DIVERSIFIED TREATMENTS WITH HIGHLY-DIFFERENTIATING AND LONG-ACTING FORMULATIONS FOR CRITICAL CHRONIC CONDITIONS

BRIEF-Ipsen Announces Presentation Of New Data During ENETS Conference

* IPSEN DATA PRESENTED DURING ENETS ANNUAL CONFERENCE 2020 CAPTURE NEW PATIENT AND HEALTHCARE PROFESSIONAL INSIGHTS IN TREATMENT OF NETS AND ACROMEGALY

BRIEF-Ipsen Sees Group Sales Growth Of Above 6% At Constant Currency In 2020

* IPSEN PRESENTS ITS 2019 RESULTS, PROVIDES 2020 GUIDANCE AND UPDATES 2022 FINANCIAL OUTLOOK

Ipsen's CEO resigns, to join Ferring unit

French healthcare company Ipsen said on Wednesday its chief executive officer, David Meek, has resigned and will take the helm at FerGene, a unit of Swiss drug company Ferring Pharmaceuticals.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up